← board
HYPD
distress 9/10 · high distress / dilution risk$2.760%today-83% from 52w high
Lead: pediatric progressive myopia
Revenue
pre-revenue
Liquidity
$7M
Runway
0.5 yrs
Shares 1y
+166%
Price & events
-5.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.4%
1W
-24.8%
1M
-29.8%
3M
-9.2%
6M
-70.4%
1Y
-97.5%
2Y
-99.2%
5Y
-99.5%
All
Overview
- Market Cap
- $41.84M
- Volume
- 62.11K
- 52 Week Range
- $2.52 – $15.97
- Total Shares
- 15.16M
- Float Shares
- 13.36M
- Short %
- 9.21%
- % Held by Insiders
- 14.10%
- % Held by Institutions
- 11.39%
- RVOL
- 0.12x
- Beta
- 2.50
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 10
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-10-28partnershipEntered Hype Asset Use Service (HAUS) agreement with Felix to support deployment of perpetual futures market on Hyperliquid, allocating 500k HYPE tokens.SEC 8-K
- 2025-10-27partnershipEntered Joint Validator Agreement with Kinetiq Group and Pier Two for co-branded validator node on Hyperliquid, effective retroactively to June 25, 2025.SEC 8-K
- 2025-10-01partnershipHYPE · Second HAUS transaction with Felix in October 2025SEC 8-K
- third quarter of 2025regulatory submissionFiled (NDA/BLA)Gen-2 Optejet device · Company expects to register Gen-2 Optejet device with FDA in Q3 2025.SEC 8-K
- 2025-09-01partnershipHYPE · First HAUS transaction with Credo in September 2025SEC 8-K
- 2025-06-25partnershipCo-branded Hyperliquid validator with Kinetiq and infrastructure support from Pier Two.SEC 8-K
- Q4 2024regulatory submissionFiled (NDA/BLA)Optejet Gen-2 · Clinical plan submitted to FDA for Gen-2 deviceSEC 8-K
- Q4 2024readoutPhase 3MicroPine · Phase 3 36-month data readoutSEC 8-K
- 2024-11-15trial discontinuedMicroPine · Company to discontinue Phase 3 CHAPERONE studySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $7 (+152% upside) · 2 analysts
- 2026-07-01Cantor FitzgeraldOverweight
- 2026-06-08Chardan CapitalBuy
- 2026-03-27Chardan CapitalBuy
- 2025-12-24Chardan CapitalBuy
- 2025-12-16Cantor FitzgeraldOverweight
- 2025-03-21HC Wainwright & Co.Neutral
Competitors — pediatric progressive myopia
- none identified
Recent news
- 2026-07-16Hyperion Deploys 500,000 HYPE to Back Skew’s HIP-3 Market Push - Yahoo Finance
- 2026-07-15Hyperion DeFi, Inc. Enters Agreement With Skew Technologies, Inc. To Launch HIP-3 Perpetual Futures Market And Listing Service - marketscreener.com
- 2026-07-15Hyperion DeFi (HYPD) Partners with Skew Technologies for Institu - GuruFocus
- 2026-07-15Hyperion DeFi Signs Deal With Skew Technologies on HIP-3 Perpetual Futures Markets - marketscreener.com
- 2026-07-15Hyperion DeFi deploys 500,000 HYPE tokens under Skew agreement - Investing.com
- 2026-07-15Hyperion DeFi จัดสรร 500,000 HYPE ภายใต้ข้อตกลง HAUS ร่วมกับ Skew Technologies เพื่อขยายตลาด Hyperliquid สำหรับนักลงทุนสถาบัน - Moomoo
- 2026-07-15Hyperion DeFi Deploys 500,000 HYPE in HAUS Agreement with Skew Technologies to Expand Institutional Hyperliquid Markets - Quiver Quantitative
- 2026-07-15Hyperion DeFi Enters Agreement With Skew Technologies to Launch HIP-3 Perpetual Futures Market and Listing Service - Moomoo
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.